Results 81 to 90 of about 45,512 (293)
British Journal of Clinical Pharmacology, EarlyView.Aims Regulatory inconsistency across Africa causes duplicative assessments, prolonged approvals, and delayed medical access. To inform the African Medicines Agency (AMA), the African Medicines Regulatory Harmonisation (AMRH) piloted Africa's first continental scientific evaluation of human medicinal products.
Alex Juma Ismail +4 more
wiley +1 more source
Clinical Anatomy, EarlyView.ABSTRACT For effective and safe practice, health professionals need an understanding of functional anatomy. Registration boards, councils or self‐regulating professional associations determine the standards, codes, graduate competencies and education program accreditation requirements which inform health curricula development and content.
Anita Zacharias +5 more
wiley +1 more source
Molecular landscape of borderline ovarian tumours: A systematic review
Open MedicineBorderline ovarian tumours (BOTs) show intriguing characteristics distinguishing them from other ovarian tumours. The aim of the systematic review was to analyse the spectrum of molecular changes found in BOTs and discuss their significance in the ...
Sadlecki Pawel +1 more
doaj +1 more source
KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations. [PDF]
Eur J HaematolABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Takaoka K +6 more
europepmc +2 more sources
Daraxonrasib and Beyond: Pan-RAS Inhibition, Resistance, and Next-Generation Strategies. [PDF]
Cancer SciABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Honda R.
europepmc +2 more sources
Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis
, 2016 International audienceThe mitogen-activated protein kinase (MAPK) pathway is constantly activated in Langerhans cell histiocytosis (LCH). Mutations of the downstream kinases BRAF and MAP2K1 mediate this activation in a subset of LCH lesions.
Mourah, Samia +10 more
core +1 more source
Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening
Clinical Pharmacology &Therapeutics, EarlyView.Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke +12 more
wiley +1 more source
Inherited genetic variants associated with melanoma BRAF/NRAS subtypes [PDF]
, 2018 BRAF and NRAS mutations arise early in melanoma development, but their associations with low-penetrance melanoma susceptibility loci remain unknown.
Rosso, Stefano +106 more
core +1 more source
NRAS is the direct target of miR-708.
, 2023 (A) Cancer cell lines with NRAS mutation used in this study. (B) Left: Representative Western blot of NRAS protein expression in SK-MEL-2, THP-1, and H1299 cells transfected with mock, scrambled control (s.c.), and precursor miR-708 (pre-miR-708) for 48 ...
Xiaowei Liang (4721025) +8 more
core +1 more source